Are you Dr. Kufe?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 60 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
D830
Boston, MA 02215Phone+1 617-632-3141Fax+1 617-632-2934- Is this information wrong?
Summary
- Dr. Donald Kufe, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Education & Training
- George Washington UniversityResidency, Internal Medicine, 1975 - 1977
- Beth Israel Deaconess Medical CenterInternship, Transitional Year, 1970 - 1971
- University of Rochester School of Medicine and DentistryClass of 1970
Certifications & Licensure
- MA State Medical License 1977 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1982
Clinical Trials
- Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1999 Mar 03
- Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 1996 Dec 01
Publications & Presentations
PubMed
- MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells.Daimon, T., Bhattacharya, A., Wang, K., Haratake, N., Nakashoji, A., Ozawa, H., Morimoto, Y., Yamashita, N., Kosaka, T., Oya, M., Kufe, D.> ;Cell Death Discovery. 2024 Jan 5
- MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells.Nami Yamashita, Henry Withers, Yoshihiro Morimoto, Atrayee Bhattacharya, Naoki Haratake, Tatsuaki Daimon, Atsushi Fushimi, Ayako Nakashoji, Aaron R Thorner, Emily Isen...> ;Iscience. 2023 Nov 17
- 2 citationsMUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokaw...> ;Journal of Thoracic Oncology. 2024 Mar 1
- Join now to see all
Press Mentions
- Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersJanuary 31st, 2023
Grant Support
- Functional Role Of The MUC1-C Oncoprotein In Non-Small Cell Lung CancerNational Cancer Institute2012
- Adoptive Immunotherapy For Multiple Myeloma Using Educated T CellsNational Cancer Institute2010–2012
- Early Clinical Trials Of New Anti-Cancer Agents With Phase I EmphasisNational Cancer Institute2008–2012
- P5 - Adoptive Immunotherapy For Renal Carcinoma Usng Dendritic Cell/Tumor FusionsNational Cancer Institute2010–2011
- Oncogenic Signaling By DF3/MUC1 In Human Breast CancerNational Cancer Institute2002–2011
- Differentiating Agents In Hematologic MalignanciesNational Cancer Institute1986–2011
- Adoptive Immunotherapy For Renal Carcinoma Using Dendritic Cell/Tumor FusionsNational Cancer Institute2009
- Novel Immunotherapeutic Approaches For Ovarian CancerNational Cancer Institute2004–2008
- Regulation Of Oxidative Stress Response By C-ABL And ARGNational Cancer Institute2003–2007
- Phase I Trials Of New Anti-Cancer AgentsNational Cancer Institute2003–2007
- Molecular Mechanisms Of ARA-C Therapy In ManNational Cancer Institute1987–2005
- Development Of Myeloma VaccinesNational Cancer Institute1998–2002
- Molecular Regulation Of Signaling By Ionizing RadiationNational Cancer Institute1996–2002
- Phase I Trials Of New Anticancer AgentsNational Cancer Institute1994–2002
- Oncogenic Signaling By The MUC1 Breast Carcinoma AntigenNational Cancer Institute2000–2001
- Phosphorylation Of RAD51National Center For Research Resources1998–2001
- Core--Cancer PharmacologyNational Cancer Institute2000
- DF3/MUC1 Vaccine And Stamp Therapy For Breast CancerNational Cancer Institute1997–1998
- Specialized Program Of Research Excellence/Breast CancerNational Cancer Institute1992–1994
- Molecular Regulation Of C-Jun By Ionizing RadiationNational Cancer Institute1992–1994
- Clonality In Acute Myeloid Leukemia And MyelodysplasiaNational Cancer Institute1991–1992
- Immunodiagnostic Approaches To Human Breast CancerNational Cancer Institute1985–1990
- Molecular Mechanisms Of ARA C Therapy In ManNational Cancer Institute1985–1986
- Molecular Mechanisms Of 5-Fluorouracil ChemotherapyNational Cancer Institute1985–1986
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts